TwoStep Therapeutics
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.
$62.5MSeries A
Role not disclosedPV
Pfizer Ventures
Activity from announced rounds
All recorded activity
Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.
Recorded funding activity
TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.
Sources
- Rounds participated in
- 6
- Confirmed lead rounds
- — 6 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $321.7M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in all activityTRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedCrossbow Therapeutics
Crossbow Therapeutics develops antibody therapies for cancer.
$77MSeries B
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedVibrant Therapeutics
Develops intelligent, logic-gated therapeutics for solid tumors
$61MSeries A
Role not disclosedEnodia Therapeutics
Develops small-molecule therapies for targeted protein degradation at the point of synthesis
€20.7MSeed
Role not disclosed